v3.25.4
Stock Incentive Plan (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Disclosure of Share-based Compensation Arrangements
For stock options, restricted shares and performance shares, the Company recorded share-based compensation expense as follows for the years ended December 31, 2025, 2024 and 2023:
Year Ended
December 31, 2025December 31, 2024December 31, 2023
Salaries, wages and employee benefits - continuing operations$11,605 $9,120 $10,090 
Salaries, wages and employee benefits - discontinued operation— — 504 
Share-based compensation expense$11,605 $9,120 $10,594 
Schedule of Weighted Average Assumptions
The weighted average grant-date fair value of the stock option awards granted and the weighted average assumptions under the Black-Scholes option-pricing model were as follows for the years ended December 31, 2025, 2024 and 2023.
December 31, 2025December 31, 2024December 31, 2023
Weighted average grant-date fair value$— $— $39.75 
Weighted average assumptions under Black-Scholes option model:
Expected dividend yield— %— %0.8 %
Expected stock price volatility— %— %32.5 %
Risk-free interest rate— %— %3.8 %
Expected life of awards (years)0.00.05.6
Schedule of Stock Option Activity
Stock option transactions during the year ended December 31, 2025 were as follows:
Number of Shares Weighted Average Exercise Price
Outstanding as of January 1280 $77.08 
Granted— — 
Exercised— — 
Forfeited or Canceled(249)72.93 
Outstanding as of December 3131 $110.26 
The following table sets forth the exercise price range, number of shares, weighted average exercise price and remaining contractual lives by groups of similar price as of December 31, 2025:

Stock Options OutstandingStock Options Exercisable
Range of Exercise PricesNumber of SharesWeighted Average Remaining Contractual Life (in years)Weighted Average Exercise PriceExercisable as of December 31, 2025Weighted Average Exercise Price
$100.93 -$115.42 31 3.6$110.26 29 $109.85 
Schedule of Restricted Share Activity
Restricted share transactions for the year ended December 31, 2025 were as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1382 $38.76 
Granted420 30.41 
Vested(162)42.93 
Forfeited(130)34.09 
Outstanding as of December 31510 $31.96 
Director restricted share transactions for the year ended December 31, 2025 were as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 118 $18.67 
Granted100 20.41 
Vested(80)20.11 
Forfeited(6)20.21 
Outstanding as of December 3132 $20.21 

Year Ended
December 31,
2025		December 31,
2024		December 31,
2023
Share-based compensation expense for director restricted shares$1,824 $984 $1,329 
Schedule of Nonvested Performance-based Units Activity The weighted average grant-date fair value of performance awards granted and the weighted average assumptions under the Monte Carlo simulation model were as follows for the years ended December 31, 2025, 2024 and 2023:
Year Ended
December 31, 2025December 31, 2024December 31, 2023
Weighted average grant-date fair value$35.56 $11.87 $120.27 
Weighted average assumptions under the Monte Carlo simulation model:
Expected stock price volatility55.7 %42.8 %37.8 %
Weighted average risk-free interest rate4.3 %4.7 %4.2 %
Schedule of Performance Award Transactions
Performance award transactions for the year ended December 31, 2025 were as follows assuming target levels of performance:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of January 1339 $15.88 
Granted208 35.56 
Forfeited or unearned (57)24.60 
Outstanding as of December 31490 $23.22 
Schedule of Employee Stock Purchase Plan
Employee stock purchase plan activity and related information was as follows:
Year Ended
December 31, 2025December 31, 2024December 31, 2023
Shares purchased by participants under the ESPP34 44 10 
Average purchase price$22.20 $17.16 $69.81 
Weighted average fair value of each purchase under the ESPP granted1
$2.47 $1.91 $7.76 
Share-based compensation expense for ESPP$89 $84 $76 
1 Equal to the discount from the market value of the common stock at the end of each six month purchase period.